<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK &#187; Uncategorized</title>
	<atom:link href="http://prostatecancerinfolink.net/category/uncategorized/feed/" rel="self" type="application/rss+xml" />
	<link>http://prostatecancerinfolink.net</link>
	<description></description>
	<lastBuildDate>Mon, 04 Jun 2012 02:59:44 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
<cloud domain='prostatecancerinfolink.net' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://s2.wp.com/i/buttonw-com.png</url>
		<title>THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK &#187; Uncategorized</title>
		<link>http://prostatecancerinfolink.net</link>
	</image>
	<atom:link rel="search" type="application/opensearchdescription+xml" href="http://prostatecancerinfolink.net/osd.xml" title="THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK" />
	<atom:link rel='hub' href='http://prostatecancerinfolink.net/?pushpress=hub'/>
		<item>
		<title>Active surveillance in the &#8220;real world&#8221; of clinical practice today</title>
		<link>http://prostatecancerinfolink.net/2012/05/27/active-surveillance-in-the-real-world-of-clinical-practice-today/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/27/active-surveillance-in-the-real-world-of-clinical-practice-today/#comments</comments>
		<pubDate>Sun, 27 May 2012 15:26:11 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[active surveillance]]></category>
		<category><![CDATA[low risk]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15701</guid>
		<description><![CDATA[A poster to be presented at the upcoming ASCO annual meeting gives us some insights into the actual behaviors of physicians and their patients regarding the use of active surveillance today in the &#8220;real world&#8221; of clinical practice (as opposed to clinical trials and case series at academic medical centers). The abstract of the poster [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15701&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/27/active-surveillance-in-the-real-world-of-clinical-practice-today/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Medivation submits NDA for MDV3100 in chemotherapy-resistant mCRPC</title>
		<link>http://prostatecancerinfolink.net/2012/05/22/medivation-submits-nda-for-mdv3100-in-chemotherapy-resistant-mcrpc/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/22/medivation-submits-nda-for-mdv3100-in-chemotherapy-resistant-mcrpc/#comments</comments>
		<pubDate>Tue, 22 May 2012 19:51:08 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15670</guid>
		<description><![CDATA[According to a media release issued late yesterday by Medivation and Astellas Pharma, Medivation has just submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval to market enzalutamide (a.k.a MDV3100). The companies have previously reported data on the effectiveness and safety of enzalutamide in the treatment of men [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15670&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/22/medivation-submits-nda-for-mdv3100-in-chemotherapy-resistant-mcrpc/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Nothing to do with prostate cancer (yet), but &#8230;</title>
		<link>http://prostatecancerinfolink.net/2012/05/18/nothing-to-do-with-prostate-cancer-yet-but/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/18/nothing-to-do-with-prostate-cancer-yet-but/#comments</comments>
		<pubDate>Fri, 18 May 2012 13:57:11 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[stem cells]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15643</guid>
		<description><![CDATA[According to an article by Andrew Pollack in today&#8217;s issue of the New York Times, a company called Osisris Therapeutics has achieved the first-ever approval to market a therapy based on stem cells &#8212; in Canada, for children with a condition known as graft versus host disease or GvHD, which is a well-recognized complication of [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15643&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/18/nothing-to-do-with-prostate-cancer-yet-but/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Abiraterone acetate may help to eliminate cancer prior to surgery in some men with high-risk, localized disease</title>
		<link>http://prostatecancerinfolink.net/2012/05/17/abiraterone-acetate-may-help-to-eliminate-cancer-prior-to-surgery-in-some-men-with-high-risk-localized-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/17/abiraterone-acetate-may-help-to-eliminate-cancer-prior-to-surgery-in-some-men-with-high-risk-localized-prostate-cancer/#comments</comments>
		<pubDate>Thu, 17 May 2012 13:52:28 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[abiraterone]]></category>
		<category><![CDATA[dutasteride]]></category>
		<category><![CDATA[enzalutamide]]></category>
		<category><![CDATA[leuprolide]]></category>
		<category><![CDATA[MDV3100]]></category>
		<category><![CDATA[neoadjuvant]]></category>
		<category><![CDATA[pre-surgical]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15631</guid>
		<description><![CDATA[According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15631&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/17/abiraterone-acetate-may-help-to-eliminate-cancer-prior-to-surgery-in-some-men-with-high-risk-localized-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>6</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Updated version of book on advanced prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/05/11/updated-version-of-book-on-advanced-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/11/updated-version-of-book-on-advanced-prostate-cancer/#comments</comments>
		<pubDate>Fri, 11 May 2012 12:23:11 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[advanced]]></category>
		<category><![CDATA[book]]></category>
		<category><![CDATA[Malecare]]></category>
		<category><![CDATA[recurrent]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15601</guid>
		<description><![CDATA[Malecare has just issued an updated version of its free book on recurrent and advanced prostate cancer. Many people have gained great benefit from the first edition of this book, and we are sure that the new version is equally useful. However, you do have to &#8220;sign up&#8221; to be able to download the new [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15601&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/11/updated-version-of-book-on-advanced-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>ProstateVideos.com web site gets face-lift and update</title>
		<link>http://prostatecancerinfolink.net/2012/05/07/prostatevideos-com-web-site-gets-face-lift-and-update/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/07/prostatevideos-com-web-site-gets-face-lift-and-update/#comments</comments>
		<pubDate>Mon, 07 May 2012 11:59:29 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[education]]></category>
		<category><![CDATA[information]]></category>
		<category><![CDATA[video]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15567</guid>
		<description><![CDATA[For those who prefer to listen to their prostate cancer updates (as opposed to those that are happy to read) the video-based web site known as ProstateVideos.com has just completed a major overhaul. In addition to providing links to over 300 brief but informative videos on everything from understanding Gleason grading to penile rehabilitation for [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15567&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/07/prostatevideos-com-web-site-gets-face-lift-and-update/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Of beehive glue and mice and prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/05/04/of-beehive-glue-and-mice-and-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/05/04/of-beehive-glue-and-mice-and-prostate-cancer/#comments</comments>
		<pubDate>Fri, 04 May 2012 18:20:02 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15565</guid>
		<description><![CDATA[According to a media report issued today, researchers at the University of Chicago have discovered that a product known as caffeic acid phenethyl ester or CAPE was able to stop the growth of prostate cancer tumors in a mouse model. CAPE is a product that can be extracted from propolis, which is a resin used [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15565&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/05/04/of-beehive-glue-and-mice-and-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>FDA approves avanafil &#8212; a new drug for erectile dysfunction</title>
		<link>http://prostatecancerinfolink.net/2012/04/30/fda-approves-avanafil-a-new-drug-for-erectile-dysfunction/</link>
		<comments>http://prostatecancerinfolink.net/2012/04/30/fda-approves-avanafil-a-new-drug-for-erectile-dysfunction/#comments</comments>
		<pubDate>Mon, 30 Apr 2012 14:15:38 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15546</guid>
		<description><![CDATA[According to a media release from Vivus, Inc., issed late on Friday, the U.S. Food &#38; Drug Administration has approved their PDE5 inhibitor avanafil (Stendra®) to the treatment of erectile dysfunction. However, we have to immediately point out that data on the activity of this drug in men who have been treated for prostate cancer [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15546&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/04/30/fda-approves-avanafil-a-new-drug-for-erectile-dysfunction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>New nanoparticle-based test may improve diagnosis of prostate cancer (in the future)</title>
		<link>http://prostatecancerinfolink.net/2012/04/26/new-nanoparticle-based-test-may-improve-diagnosis-of-prostate-cancer-in-the-future/</link>
		<comments>http://prostatecancerinfolink.net/2012/04/26/new-nanoparticle-based-test-may-improve-diagnosis-of-prostate-cancer-in-the-future/#comments</comments>
		<pubDate>Thu, 26 Apr 2012 17:10:24 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15519</guid>
		<description><![CDATA[An article in the Journal of Translational Medicine (in conjunction with a media release from the University of Central Florida) has described a new test that &#8212; according to the media release &#8212; may be able to further discriminate between indolent and clinically significant forms of prostate cancer. The test developed by Quon Hu0 and [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15519&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/04/26/new-nanoparticle-based-test-may-improve-diagnosis-of-prostate-cancer-in-the-future/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>ASCO updates patient information on managing cost of cancer care</title>
		<link>http://prostatecancerinfolink.net/2012/04/16/asco-publishes-patient-information-on-managing-cost-of-cancer-care/</link>
		<comments>http://prostatecancerinfolink.net/2012/04/16/asco-publishes-patient-information-on-managing-cost-of-cancer-care/#comments</comments>
		<pubDate>Mon, 16 Apr 2012 12:43:39 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[cost]]></category>
		<category><![CDATA[help]]></category>
		<category><![CDATA[support]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15450</guid>
		<description><![CDATA[The costs associated with the treatment of prostate cancer &#8212; particularly the more advanced forms of prostate cancer that require sophisticated forms of drug therapy &#8212; can be considerable. Patients often benefit from help and assistance in negotiating these costs and in handling the various needs of their physicians, their insurance companies, and Medicare or even Medicaid. [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15450&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/04/16/asco-publishes-patient-information-on-managing-cost-of-cancer-care/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>

		<media:content url="http://talkaboutprostatecancer.files.wordpress.com/2012/04/cost_of_care_cover.jpg" medium="image">
			<media:title type="html">Cost_of_Care_Cover</media:title>
		</media:content>
	</item>
		<item>
		<title>LUGPA reacts to suggestions of excessive prostate biopsies in Health Affairs</title>
		<link>http://prostatecancerinfolink.net/2012/04/13/lugpa-reacts-to-suggestions-of-excessive-prostate-biopsies-in-health-affairs/</link>
		<comments>http://prostatecancerinfolink.net/2012/04/13/lugpa-reacts-to-suggestions-of-excessive-prostate-biopsies-in-health-affairs/#comments</comments>
		<pubDate>Fri, 13 Apr 2012 18:38:12 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[biopsy]]></category>
		<category><![CDATA[cores]]></category>
		<category><![CDATA[prostate]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15437</guid>
		<description><![CDATA[Not surprisingly, a major urology organization (the Large Urology Group Practice Association or LUGPA) has aggressively disputed the findings recently published by Mitchell in Health Affairs regarding the numbers of prostate biopsies conducted by urology groups with in-house pathology laboratories (see earlier commentary). The media release from LUGPA questions everything from the motivations behind Mitchell&#8217;s [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15437&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/04/13/lugpa-reacts-to-suggestions-of-excessive-prostate-biopsies-in-health-affairs/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>FDA updates risks of adverse effects from treatment with finasteride</title>
		<link>http://prostatecancerinfolink.net/2012/04/13/fda-updates-risks-of-adverse-effects-from-terament-with-finasteride/</link>
		<comments>http://prostatecancerinfolink.net/2012/04/13/fda-updates-risks-of-adverse-effects-from-terament-with-finasteride/#comments</comments>
		<pubDate>Fri, 13 Apr 2012 15:38:26 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[adverse]]></category>
		<category><![CDATA[effect]]></category>
		<category><![CDATA[finasteride]]></category>
		<category><![CDATA[side]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15434</guid>
		<description><![CDATA[The U.S. Food &#38; Drug Adminstration (FDA), yesterday, issued a statement about modifications to the labeling (the product prescribing information) for the two branded formulations of finasteride: Propecia® (finasteride 1 mg) and Proscar® (finasteride 5 mg). These modifications to the product labeling may be relevant to some men with or at risk for prostate cancer. [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15434&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/04/13/fda-updates-risks-of-adverse-effects-from-terament-with-finasteride/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Itraconazole in treatment of mCRPC: an update</title>
		<link>http://prostatecancerinfolink.net/2012/04/09/itraconazole-in-treatment-of-mcrpc-an-update/</link>
		<comments>http://prostatecancerinfolink.net/2012/04/09/itraconazole-in-treatment-of-mcrpc-an-update/#comments</comments>
		<pubDate>Mon, 09 Apr 2012 12:52:14 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[castration-resistant]]></category>
		<category><![CDATA[itraconazole]]></category>
		<category><![CDATA[mCRPC]]></category>
		<category><![CDATA[metastatic]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15394</guid>
		<description><![CDATA[Researchers at Johns Hopkins have, for a while, been investigating the potential of the antifungal agent itraconazole as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). We last reported on this research nearly a year ago, based on a presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15394&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/04/09/itraconazole-in-treatment-of-mcrpc-an-update/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Fred Gersh &#8230; Requiescat in pace</title>
		<link>http://prostatecancerinfolink.net/2012/04/05/fred-gersh-requiescat-in-pace/</link>
		<comments>http://prostatecancerinfolink.net/2012/04/05/fred-gersh-requiescat-in-pace/#comments</comments>
		<pubDate>Thu, 05 Apr 2012 15:20:33 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15384</guid>
		<description><![CDATA[Most readers of this column will never have heard of Fred Gersh; a few may have spoken to him or e-mailed him or actually met him. Fred passed away early this morning as a consequence of metastatic, castration- and chemotherapy-refractory disease 23 years after his initial diagnosis with prostate cancer. Fred was a tireless advocate [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15384&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/04/05/fred-gersh-requiescat-in-pace/feed/</wfw:commentRss>
		<slash:comments>10</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>

		<media:content url="http://talkaboutprostatecancer.files.wordpress.com/2012/04/fred-gersh2.jpg" medium="image">
			<media:title type="html">Fred Gersh2</media:title>
		</media:content>
	</item>
		<item>
		<title>Patenting of genes and related issues: Supreme Court makes two decisions</title>
		<link>http://prostatecancerinfolink.net/2012/03/27/patenting-of-genes-and-related-issues-supreme-court-makes-two-decisions/</link>
		<comments>http://prostatecancerinfolink.net/2012/03/27/patenting-of-genes-and-related-issues-supreme-court-makes-two-decisions/#comments</comments>
		<pubDate>Tue, 27 Mar 2012 15:46:35 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15315</guid>
		<description><![CDATA[As regular readers will be aware, the Supreme Court of the United States (SCOTUS) had recently delayed any decision on a case related to the rights of Myriad Genetics to hold and enforce use patents related to the BRCA1 and BRCA2 genes associated with the diagnosis of specific subtypes of breast and ovarian cancer. Yesterday, [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=15315&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/03/27/patenting-of-genes-and-related-issues-supreme-court-makes-two-decisions/feed/</wfw:commentRss>
		<slash:comments>6</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
	</channel>
</rss>
